In the cell world model,
Life science“Trial and error”To finish.
Technology/Service
Concept
Of the cell“World”Toward AI that understands and predicts the future
Sekai Biotech is building a next-generation life science platform that tightly integrates automated experimental systems, reinforcement learning, and world models to predict and control cell state changes. This will support the advancement of drug discovery compound screening, toxicity assessment, and disease model development.
Solution
Forward prediction andReverse lookup generationbut it will transform life science exploration
The cell world model has two core capabilities: "forward prediction" and "backward generation." This bidirectionality enables intelligent exploration beyond traditional trial and error.
Technology
Integrating AI and experimentationClosed loopAutonomous Experimentation Platform
Designed as an integrated closed-loop system without separating AI models and experimental systems. The AI continuously handles everything from hypothesis generation, experimental design, execution, result analysis, and then to the next hypothesis generation. This autonomously and continuously progresses through experimental cycles to acquire a world model and improve reinforcement learning performance.
About Us
Sekai Biotech is building a next-generation life science platform that tightly integrates automated experimental systems, reinforcement learning, and world models to predict and control cell state changes. This will support the advancement of drug discovery compound screening, toxicity assessment, and disease model development.
Company Profile
Company Name
Sekai Biotech, Inc.
Business activities
Development of disease evaluation models and toxicity evaluation models using cell-based world models
Establishment
May 25, 2026
Representative
Representative Director Toshi Fuku Kawakami
Principal shareholder
Advanced Technologies Co-creation Organization, Ltd.
Team
Representative Director
Tofuku Kawakami
Joined IGPI after working at a trading company and GE. Oversaw projects in advanced technology commercialization, startup support, industry-academia collaboration, AI/DX, business development, and organizational HR.
Director/Founder
Kiyota Jun
After cardiovascular surgery training, I obtained a PhD in Stem Cell Biology.
Conducting interdisciplinary research at Stanford University merging cell biology with data science and machine learning.
Research on deep learning in medicine and biology at RIKEN since 2016
Executive Officer
Tsuchida Yasushi
Graduated from Tohoku University School of Medicine and obtained a medical license. Led strategy development and R&D investment support for biopharmaceutical companies at Incubation Partners. Joined Advanced Technology Creation Organization (ATAC) in 2022 and spearheaded the commercialization of drug discovery seeds from academia.
Executive Officer
Masatoshi Mikami
After engaging in tax services at a tax accountant corporation, I gained experience in a wide range of duties at a Tokyo Stock Exchange Mothers-listed company, including IPO preparation, accounting and finance, taxation, and the creation of disclosure documents. Subsequently, I joined IGPI, where I became responsible for the accounting and finance operations of the entire IGPI group and tax matters, including group tax consolidation. I also supported numerous startups as an investor, assisting them in establishing and operating their accounting and tax systems.